Coverage Initiated on Developer of Targeted Gene Therapies for Cancer
Source: Streetwise Reports  (11/7/18)
A LifeSci Capital report highlighted the advantages of this biotech story's lead candidate targeting bladder cancer. More >

Selectively Targeting Alzheimer's Disease's Root Cause Is Key, Biotech Says
Source: Streetwise Reports  (11/7/18)
This firm explains how its 15 years in drug development led to and supports this conclusion. More >

Hemp Sales Grow at CV Sciences: Q3 Beats Estimates, 2019 Outlook
Source: Fincom Investment Partners for Streetwise Reports  (11/7/18)
Fincom Investment Partners takes a look at Q3 earnings for a U.S.-based CBD company and explains why it believes it offers good value. More >

A Canadian Cannabis Company for the Next Wave
Source: Ron Struthers for Streetwise Reports  (11/6/18)
Ron Struthers, who believes the ideal marijuana stock to buy at this time is one that is focused on cannabis oil, profiles one such company that he sees as undervalued. More >

Biotech’s Lead Drug Candidate Targets 'Market with Huge Potential'
Source: Streetwise Reports  (10/31/18)
A ROTH Capital Partners report outlines its reasons for initiating coverage on this epigenetic therapeutics developer, whose lead candidate is in trials in diabetes, end-stage renal disease and other indications. More >

Biotech Pinpoints Third Set of Targets for Potential Alzheimer's Treatment
Source: Streetwise Reports  (10/31/18)
With this achievement, the firm expands its potential partnering opportunities. More >

Three Small-Caps on This Fund Manager's List
Source: Streetwise Reports  (10/30/18)
Steve Palmer, founding partner, President and Chief Investment Officer of AlphaNorth Asset Management, talks with Streetwise Reports about several small-cap companies from three sectors that he has been following. More >

Update on Stock in Vanguard of Drive to Phase Out Antibiotics in Animal Feed
Source: Clive Maund for Streetwise Reports  (10/29/18)
Technical analyst Clive Maund provides an update on a company whose product is replacing antibiotics for growth promotion in animal feed. More >

This Biotech, Whose Discovery Could End Routine Antibiotic Use in Livestock, Is the Pick of Three Fund Managers
Source: Streetwise Reports  (10/27/18)
Multiple governments around the world have unleashed mandates on livestock feed regulations that pose an opportunity for a Canada-based biotech company. More >

As Anixa Starts Approaching the FDA, We Discuss Its Two Innovative Programs
Source: Daniel Carlson for Streetwise Reports  (10/27/18)
Dr. Amit Kumar, CEO of Anixa Biosciences, sits down with Daniel Carlson of Tailwinds Research to discuss the company's trials of CAR-T for solid tumors, as well as its Cchek program to distinguish between benign conditions and malignant cancer. More >

Catasys…Future's So Bright
Source: Daniel Carlson for Streetwise Reports  (10/27/18)
Daniel Carlson of Tailwinds Research discusses a company that helps health plans solve the hidden, high-cost problem of untreated behavioral health conditions. More >

Biotech to Expand Precision Medicine Services via New Partnership
Source: Streetwise Reports  (10/24/18)
A Maxim Group report discussed the potential implications of this new collaboration in the field of personalized medicine and oncology. More >

Hemp Producer CV Sciences' Q3 Earnings Estimates--Our View
Source: Fincom Investment Partners for Streetwise Reports  (10/24/18)
Fincom Investment Partners previews Q3 earnings estimates for a company that it believes offers the best value in cannabis/hemp. More >

Animal Health Product Developer to Expand Sales Footprint
Source: Streetwise Reports  (10/20/18)
This Canadian company makes progress with its commercial uptake efforts. More >

Biotech Advances Monoclonal Antibody Technology and Is Awarded Gates Foundation Grant
Source: Streetwise Reports  (10/20/18)
An H.C. Wainwright & Co. report delivered the latest news regarding one of this immunotherapy firm's platforms, including the receipt of the first-ever U.S. patents for DNA-encoded monoclonal antibody technology. More >

Groundbreaking Biotech Company Takes Major Step Forward with Deal with Chinese Partner
Source: Streetwise Reports  (10/17/18)
Canada-based biotech company signs major deal with Chinese partner to advance groundbreaking technology in the skin and tendon rejuvenation space. More >

Biotech Reports Encouraging Interim Gene Therapy Data for Skin Disorder
Source: Streetwise Reports  (10/17/18)
This company's findings to date for its topical therapy candidate have encouraging implications for an orphan indication. More >

Tech Firm Launches Medical Cannabis User Data App, Lands Partnership
Source: Streetwise Reports  (10/13/18)
This "patient-care solution" is designed to help retailers make product recommendations. More >

Biotech's Antibodies Target Toxic Oligomers Implicated in Parkinson's Disease
Source: Streetwise Reports  (10/11/18)
Testing conducted as part of this Canadian company's research and development work on Parkinson's disease therapeutics has identified new potential antibody candidates. More >

This Biotech Is 'Harnessing the Microbiome's Therapeutic Potential'
Source: Streetwise Reports  (10/10/18)
A LifeSci Capital report presented a handful of key points about the firm. More >

FDA Approves Biopharma's Drug with $1.75 Billion Peak Sales Potential
Source: Streetwise Reports  (10/10/18)
An H.C. Wainwright & Co. report covered the greenlighting of two therapeutics developed by this firm, whose stock, according to the analyst, has more than fivebagger return potential. More >

Texas Heart Takes to the CoreoGraft
Source: Daniel Carlson for Streetwise Reports  (10/10/18)
Daniel Carlson of Tailwinds Research profiles Hancock Jaffe Laboratories, which is partnering with the Texas Heart Institute to further develop an innovative graft designed for use in coronary bypass surgery. More >

Developer of Nitric Oxide Delivery Devices Rebrands to Focus on Leading Advancements
Source: Streetwise Reports  (10/9/18)
This Utah-based company rolled out an online campaign that highlights its strategic repositioning. More >

DURECT Receives Return on Schizophrenia Drug Approval
Source: Streetwise Reports  (10/3/18)
A new, once-monthly injectable treatment for schizophrenia uses patents of a small-cap, U.S.-based pharmaceutical firm. More >

Company with Cancer Radiotherapy Grows Revenue for Six Consecutive Quarters
Source: Streetwise Reports  (10/3/18)
An H.C. Wainwright & Co. report reviewed this company's Q4/18 earnings and opportunities for increasing it. More >